Year None2022202120202019201820172016 June 22, 2022 Medicenna Reports Fiscal Year 2022 Financial Results and Operational Highlights Go to June 9, 2022 Medicenna Strengthens Intellectual Property Protection for Superkine Platform with Issuance of U.S. Patent Go to June 7, 2022 Medicenna to Announce Fiscal Year 2022 Financial Results and Operational Highlights on Wednesday, June 22, 2022 Go to May 11, 2022 Medicenna Presents Phase 1/2 ABILITY Study Data Highlighting MDNA11’s Favorable Clinical Profile at the 2022 Frontiers in Cancer Immunotherapy Meeting Go to May 2, 2022 Medicenna Announces New Clinical Data Showing Dose-Dependent Stimulation of Anti-Cancer Immune Cells with MDNA11 in the Phase 1/2 ABILITY Study Go to April 27, 2022 Medicenna Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference Go to Pagination Current page 1 Page 2 Page 3 Next page next › Last page last »
June 9, 2022 Medicenna Strengthens Intellectual Property Protection for Superkine Platform with Issuance of U.S. Patent Go to
June 7, 2022 Medicenna to Announce Fiscal Year 2022 Financial Results and Operational Highlights on Wednesday, June 22, 2022 Go to
May 11, 2022 Medicenna Presents Phase 1/2 ABILITY Study Data Highlighting MDNA11’s Favorable Clinical Profile at the 2022 Frontiers in Cancer Immunotherapy Meeting Go to
May 2, 2022 Medicenna Announces New Clinical Data Showing Dose-Dependent Stimulation of Anti-Cancer Immune Cells with MDNA11 in the Phase 1/2 ABILITY Study Go to
April 27, 2022 Medicenna Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference Go to
